SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development

Executive Summary

• SureNano Science Ltd. completed the acquisition of GlucaPharm Inc., adding a next‑generation GLP therapeutic (GEP44) to its pipeline and shifting toward a pharmaceutical value creator.
• The transaction was structured as a share exchange: 8,100,999 SureNano common shares issued to GlucaPharm shareholders plus warrants for 5,000,000 additional shares.
• Dr. Nihar R. Pandey was appointed Director and Chief Scientific Officer, bolstering the company’s scientific leadership.

Key Details

• Consideration: 8,100,999 SureNano common shares issued to GlucaPharm shareholders; warrants to purchase 5,000,000 SureNano common shares issued to holders of GlucaPharm warrants (per Nov 19 2025 press release).
• Hold Period Legend: Shares may not be sold, transferred, hypothecated or otherwise traded until the later of CSE approval of SureNano’s 2026 Annual Form 5A and release of the 2026 audited financial statements.
• Asset Acquired: GlucaPharm’s patented peptide GEP44 – a second‑generation GLP‑1 candidate with preclinical data showing significant weight loss and glucose normalization without typical nausea/GI side effects.
• Licensing: GEP44 exclusively licensed from Syracuse University; potential non‑injectable delivery routes (oral, sublingual, nasal).
• Development Plan: IND‑enabling FDA study in collaboration with an Australian CRO; Phase I clinical trial expected to commence in Australia within the next few months. Key milestones anticipated over 6–9 months (IND progression, early clinical validation).
• Strategic Fit: Acquisition accelerates SureNano’s transition from surfactant technology provider to a near‑term pharmaceutical platform targeting the fast‑growing GLP‑1 metabolic market (multi‑hundred‑billion‑dollar opportunity).
• Financing Support: SureNano recently completed $1.25 M financing (warrants exercisable at $0.35) on Dec 10 2025 to fund near‑term development and future funding rounds.
• Management Appointment: Dr. Nihar R. Pandey appointed Director & Chief Scientific Officer; 25+ years in drug discovery, IP‑protected formulations, regulatory compliance, former Group Leader at Liponex Inc.

Notable Quotes

“This acquisition marks a transformational milestone for SureNano,” said Charles MaLette, CEO of SureNano Science Ltd. “GlucaPharm provides the Company with a highly differentiated GLP asset at a time when demand for effective, better‑tolerated metabolic therapies continues to accelerate globally.”

Materiality Assessment: Material – Positive (the acquisition materially expands SureNano’s pipeline and market positioning in a high‑growth therapeutic area).